Extracorporeal ultrafiltration vs conventional diuretic therapy in advanced decompensated heart failure

Congestive Heart Failure

Volumn 18, Issue 1, 2012, Pages 54-63

  Hanna, Mazen A ^a   Wilson Tang, W H ^a   Teo, Boon W ^a   O'Neill, James O ^a   Weinstein, David M ^a   Lau, Sey M ^a   van Lente, Frederick ^a   Starling, Randall C ^a   Paganini, Emil P ^a   Taylor, David O ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SODIUM;

ADULT; ADVANCED DECOMPENSATED HEART FAILURE; ARTICLE; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CONVENTIONAL DIURETIC THERAPY; CREATININE BLOOD LEVEL; DETERIORATION; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; EXTRACORPOREAL ULTRAFILTRATION; FEMALE; HEART FAILURE; HEART RATE; HEMODIALYSIS; HEMODYNAMICS; HUMAN; HYPOTENSION; INFECTION; INTERMETHOD COMPARISON; KIDNEY FUNCTION; LENGTH OF STAY; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; SAFETY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT REDUCTION;

DIURETICS; FEMALE; HEART FAILURE; HEMODYNAMICS; HEMOFILTRATION; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OHIO; PROSPECTIVE STUDIES; PULMONARY WEDGE PRESSURE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856241244     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00231.x     Document Type: Article

References (30)

1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38:2101-2113.
2. Klein L, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol. 2003; 91:18F-40F.
3. New York Heart Association. Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis, 6th ed. Boston, MA: Little; 1964, Xxiii.
4. Jain P, et al. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Am Heart J. 2003;2(suppl):S3-S17.
5. Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46:2047-2051.
6. Agostoni PG, Marenzi GC, Pepi M, et al. Isolated ultrafiltration in moderate congestive heart failure. J Am Coll Cardiol. 1993;21:424-431.
7. Bart BA, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46:2043-2046.
8. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675-683.
9. Forslund T, Riddervold F, Fauchald P, et al. Hormonal changes in patients with severe chronic congestive heart failure treated by ultrafiltration. Nephrol Dial Transplant. 1992;7:306-310.
10. Marenzi G, Grazi S, Giraldi F, et al. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration. Am J Med, 1993;94:49-56.
11. Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994;96:191-199.
12. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97:282-289.
13. Francis G.S., Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
14. Katz AM. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med. 1994; 121:363-371.
15. Vasan RS, Sullivan LM, Roubenoff R, Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486-1491.
16. Marin J, Marin E, Gutierrez-Iniquez MA, et al. Mechanisms involved in the hemodynamic alterations in congestive heart failure as a basis for a rational pharmacological treatment. Pharmacol Ther. 2000;88:15-31.
17. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003; 107:2690-2696.
18. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
19. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37:379-385.
20. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571-579.
21. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246-253.
22. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
23. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med. 1990;9:65-71.
24. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton: Chapman & Hall/CRC; 2000, Xviii.
25. Liang KV, Hiniker AR, Williams AW, et al. Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center. J Card Fail. 2006;12:707-714.
26. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6.
27. Cole L, Bellomo R, Hart G, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med. 2002;30:100-106.
28. Fonaraow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in clinical characteristics, treatments and outcomes for heart failure hospitalizations; 2002 to 2004: findings from the Acute Decompensated Heart failure National Registry (AHDERE). Am Heart J. 2007;153:1021-1028.
29. Paganini EP, Fouad F, Tarazi RC, et al. Hemodynamics of isolated ultrafiltration in chronic hemodialysis patients. Trans Am Soc Artif Intern Organs, 1979; 25:422-425.
30. Blake P, Paganini EP, et al. Refractory congestive heart failure: overview and application of extracorporeal ultrafiltration. Adv Ren Replace Ther. 1996;3:166-173.